- $557.31m
- $554.58m
- $311.71m
Annual balance sheet for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 65.5 | 58.8 | 76 | 51.7 | 149 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.045 | 0 | — | 51.7 | 171 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 66.5 | 59.6 | 79.5 | 115 | 367 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.37 | 2.38 | 2.51 | 2.32 | 9.93 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 68.9 | 62 | 82.1 | 119 | 826 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.35 | 6.31 | 11.4 | 33.8 | 174 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.15 | 6.98 | 11.9 | 34.2 | 421 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 62.8 | 55.1 | 70.1 | 84.7 | 405 |
| Total Liabilities & Shareholders' Equity | 68.9 | 62 | 82.1 | 119 | 826 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |